Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.41 |
| ▸ | PEPD | P12955 | 2/20 | 0.39 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913398 | 1.00 | POLB (0.46) | POLBFKBP1APEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL24928818 | 0.94 | POLB (0.42) | POLBFKBP1APEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL24434718 | 0.93 | POLB (0.44) | POLBFKBP1ASMN1; SMN2CNR2CNR1 | |
| SCHEMBL12881541 | 0.90 | FKBP1A (0.44) | POLBFKBP1APEPDXPNPEP1CNR2 | |
| SCHEMBL17001850 | 0.90 | FKBP1A (0.44) | POLBFKBP1APEPDXPNPEP1CNR2 | |
| SCHEMBL20909019 | 0.90 | FKBP1A (0.44) | POLBFKBP1APEPDXPNPEP1CNR2 | |
| SCHEMBL1207488 | 0.88 | POLB (0.41) | POLBFKBP1APEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL17001994 | 0.88 | POLB (0.41) | POLBFKBP1APEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL6193034 | 0.87 | SMN1; SMN2 (0.42) | POLBFKBP1ASMN1; SMN2CNR2CNR1 | |
| SCHEMBL16992411 | 0.87 | POLB (0.40) | POLBFKBP1APEPDXPNPEP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076523-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-114591299-A | Paroviride intermediate and preparation and application thereof | 雅本化学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | CONCERT PHARMACEUTICALS, INC. | 2012-09-27 | — | — | US | disclosed |
| WO-2010138889-A1 | PEPTIDES FOR THE TREATMENT OF HCV INFECTIONS | CONCERT PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-2222324-A2 | BOCEPREVIR DERIVATIVES FOR THE TREATMENT OF HCV INFECTIONS | CONCERT PHARMACEUTICALS, INC. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090175824-A1 | Peptides for the treatment of HCV infections | CONCERT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2009067225-A2 | BOCEPREVIR DERIVATIVES FOR THE TREATMENT OF HCV INFECTIONS | CONCERT PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175824-A1 | Peptides for the treatment of HCV infections | DPP4, ZC3HAV1, CTSC | POLB 3816/4885FKBP1A 903/4885PEPD 4/4885 |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | HAVCR2, VIP, PEPD | POLB 3725/4885FKBP1A 1413/4885PEPD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.